Sixty-four patients with PLA2R1-associated membranous nephropathy were randomly assigned (1:1) to the GEMRITUX protocol (symptomatic treatment for six months followed by two 375 mg/m2 rituximab infusions at month-6 in case of persistent nephrotic syndrome) or to the personalized protocol (patients without epitope spreading at month-0/month-6 followed the GEMRITUX protocol, while patients with epitope spreading at month-0/month-6 were treated immediately with two 1 g rituximab infusions). Here, PLA2R1 is linked to membranous glomerulonephritis.